Skandinaviska Enskilda Banken (SEB)’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-347,671
Closed -$374M 471
2025
Q4
$374M Sell
347,671
-11,471
-3% -$11M 1.5% 9
2025
Q3
$274M Buy
359,142
+30,128
+9% +$22.4M 1.1% 13
2025
Q2
$256M Buy
329,014
+7,629
+2% +$5.93M 1.12% 13
2025
Q1
$265M Sell
321,385
-15,214
-5% -$12.7M 1.31% 12
2024
Q4
$260M Buy
336,599
+4,722
+1% +$3.91M 1.18% 14
2024
Q3
$294M Sell
331,877
-2,405
-0.7% -$2.16M 1.36% 11
2024
Q2
$303M Sell
334,282
-10,242
-3% -$8.19M 1.45% 9
2024
Q1
$268M Sell
344,524
-1,925
-0.6% -$1.37M 1.31% 13
2023
Q4
$202M Sell
346,449
-11,611
-3% -$6.78M 1.17% 13
2023
Q3
$192M Sell
358,060
-2,854
-0.8% -$1.47M 1.26% 13
2023
Q2
$169M Buy
360,914
+3,186
+0.9% +$1.34M 1.11% 14
2023
Q1
$123M Sell
357,728
-15,517
-4% -$5.23M 0.86% 21
2022
Q4
$137M Sell
373,245
-4,976
-1% -$1.76M 1.03% 12
2022
Q3
$122M Sell
378,221
-82,463
-18% -$26.1M 0.94% 17
2022
Q2
$149M Buy
460,684
+8,243
+2% +$2.47M 1.1% 12
2022
Q1
$130M Buy
452,441
+5,389
+1% +$1.39M 0.76% 21
2021
Q4
$124M Sell
447,052
-39,459
-8% -$10M 0.64% 30
2021
Q3
$112M Buy
486,511
+11,062
+2% +$2.73M 0.62% 29
2021
Q2
$109M Sell
475,449
-73,742
-13% -$14.8M 0.67% 23
2021
Q1
$103M Buy
549,191
+12,815
+2% +$2.51M 0.68% 26
2020
Q4
$90.6M Sell
536,376
-104,778
-16% -$15.6M 0.62% 25
2020
Q3
$94.9M Sell
641,154
-3,027
-0.5% -$468K 0.69% 31
2020
Q2
$106M Sell
644,181
-1,737
-0.3% -$267K 0.85% 20
2020
Q1
$89.6M Buy
645,918
+196,916
+44% +$27.1M 0.91% 23
2019
Q4
$59M Buy
449,002
+17,171
+4% +$1.99M 0.46% 51
2019
Q3
$48.3M Buy
431,831
+19,743
+5% +$2.2M 0.41% 58
2019
Q2
$45.7M Sell
412,088
-24,843
-6% -$2.93M 0.39% 63
2019
Q1
$56.7M Buy
436,931
+60,063
+16% +$7.3M 0.52% 50
2018
Q4
$43.6M Sell
376,868
-219,050
-37% -$24.5M 0.39% 56
2018
Q3
$63.9M Sell
595,918
-213,400
-26% -$21.3M 0.49% 48
2018
Q2
$69.1M Buy
809,318
+37,096
+5% +$3.05M 0.59% 43
2018
Q1
$59.7M Sell
772,222
-56,071
-7% -$4.51M 0.58% 45
2017
Q4
$70M Buy
828,293
+200,753
+32% +$17.1M 0.6% 44
2017
Q3
$53.7M Buy
627,540
+454,385
+262% +$37.3M 0.49% 51
2017
Q2
$14.3M Buy
173,155
+4,370
+3% +$357K 0.14% 146
2017
Q1
$14.2M Buy
168,785
+741
+0.4% +$59.4K 0.14% 132
2016
Q4
$12.4M Sell
168,044
-15,829
-9% -$1.18M 0.15% 119
2016
Q3
$14.8M Buy
183,873
+5,153
+3% +$412K 0.16% 108
2016
Q2
$14.1M Buy
178,720
+7,290
+4% +$549K 0.16% 103
2016
Q1
$12.3M Sell
171,430
-1,719,494
-91% -$130M 0.14% 121
2015
Q4
$159M Buy
+1,890,924
New +$157M 2.06% 13

Other funds holding LLY

Skandinaviska Enskilda Banken (SEB)'s LLY Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 347,671 shares — an estimated $374M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in LLY in Q4 2015 and held it in 41 quarters. The position peaked at $374M in Q4 2025. 4,378 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 347,671 Eli Lilly shares in Q1 2026, an estimated $374M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Eli Lilly in Q4 2015 and held it in 41 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Eli Lilly position peaked at $374M in Q4 2025.
  • 4,378 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.